Tags

Type your tag names separated by a space and hit enter

[Clinical evaluation of a selective inhibitor of cholesterol synthesis: pravastatin].
Minerva Med. 1992 Nov; 83(11):677-93.MM

Abstract

The recent introduction in clinical practice of a new class of drugs able to reduce the endogenous synthesis of cholesterol has undoubtedly made a noteworthy contribution to the treatment of hypercholesterolaemia which, as is well known, is one of the greatest risk factors in the natural history of atherosclerotic disease and of its cardiovascular complications. A last generation drug belonging to this family is pravastatin which differs from the other substances inhibiting the activity of the key enzyme of cholesterol metabolism, HMGCaA reductase, because of certain features of the molecule, such as hydrophilia and the fact it is already pharmacologically active at the moment of oral administration. Pravastatin, which is probably a special category of HMGCoA reductase inhibitor, has shown, in numerous experimental studies and controlled clinical trials, a notable effectiveness in reducing in a highly selective fashion the synthesis of cholesterol in the liver cells and consequently the number of cholesterol-rich lipoproteins in the systemic circulation, without also determining significant biologically negative side-effects.

Authors+Show Affiliations

Alessandri C
Università degli Studi di Roma La Sapienza, Roma.
Peverini F
No affiliation info available

MeSH

AdultAnimalsAnticholesteremic AgentsCholesterolCholestyramine ResinClinical Trials as TopicDrug Therapy, CombinationFemaleGuinea PigsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaLovastatinMalePravastatinRatsRisk FactorsSimvastatinTime Factors

Pub Type(s)

Comparative Study
English Abstract
Journal Article
Review

Language

ita

PubMed ID

1461539

Citation

Alessandri, C, and F Peverini. "[Clinical Evaluation of a Selective Inhibitor of Cholesterol Synthesis: Pravastatin]." Minerva Medica, vol. 83, no. 11, 1992, pp. 677-93.
Alessandri C, Peverini F. [Clinical evaluation of a selective inhibitor of cholesterol synthesis: pravastatin]. Minerva Med. 1992;83(11):677-93.
Alessandri, C., & Peverini, F. (1992). [Clinical evaluation of a selective inhibitor of cholesterol synthesis: pravastatin]. Minerva Medica, 83(11), 677-93.
Alessandri C, Peverini F. [Clinical Evaluation of a Selective Inhibitor of Cholesterol Synthesis: Pravastatin]. Minerva Med. 1992;83(11):677-93. PubMed PMID: 1461539.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Clinical evaluation of a selective inhibitor of cholesterol synthesis: pravastatin]. AU - Alessandri,C, AU - Peverini,F, PY - 1992/11/1/pubmed PY - 1992/11/1/medline PY - 1992/11/1/entrez SP - 677 EP - 93 JF - Minerva medica JO - Minerva Med VL - 83 IS - 11 N2 - The recent introduction in clinical practice of a new class of drugs able to reduce the endogenous synthesis of cholesterol has undoubtedly made a noteworthy contribution to the treatment of hypercholesterolaemia which, as is well known, is one of the greatest risk factors in the natural history of atherosclerotic disease and of its cardiovascular complications. A last generation drug belonging to this family is pravastatin which differs from the other substances inhibiting the activity of the key enzyme of cholesterol metabolism, HMGCaA reductase, because of certain features of the molecule, such as hydrophilia and the fact it is already pharmacologically active at the moment of oral administration. Pravastatin, which is probably a special category of HMGCoA reductase inhibitor, has shown, in numerous experimental studies and controlled clinical trials, a notable effectiveness in reducing in a highly selective fashion the synthesis of cholesterol in the liver cells and consequently the number of cholesterol-rich lipoproteins in the systemic circulation, without also determining significant biologically negative side-effects. SN - 0026-4806 UR - https://www.unboundmedicine.com/medline/citation/1461539/[Clinical_evaluation_of_a_selective_inhibitor_of_cholesterol_synthesis:_pravastatin]_ DB - PRIME DP - Unbound Medicine ER -